Catherine M. Szyman - Feb 13, 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Feb 13, 2024
Transactions value $
-$2,313,604
Form type
4
Date filed
2/15/2024, 05:25 PM
Previous filing
Oct 10, 2023
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $735K +20K +57.45% $36.75 54.8K Feb 13, 2024 Direct
transaction EW Common Stock Sale -$1.73M -20K -36.49% $86.46 34.8K Feb 13, 2024 Direct F1
transaction EW Common Stock Options Exercise $992K +27K +77.56% $36.75 61.8K Feb 15, 2024 Direct
transaction EW Common Stock Sale -$2.31M -27K -43.68% $85.62 34.8K Feb 15, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -20K -42.55% $0.00 27K Feb 13, 2024 Common Stock 20K $36.75 Direct
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -27K -100% $0.00* 0 Feb 15, 2024 Common Stock 27K $36.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $86.00 to $86.81. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $85.44 to $85.83. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person